Article infectious diseases

Varicella
Robin English, MD*
Objectives After completing this article, readers should be able to:

1. Discuss the consequences of primary infection with varicella-zoster virus and

reactivation.
2. Describe the ramifications of group A Streptococcus infection.
3. Identify those in whom varicella infection is most severe.
4. Explain the treatment options for varicella.
5. Recognize how to prevent varicella.

Introduction
Varicella is a common exanthematous disease that primarily affects children. In general,
clinicians are very familiar with the clinical presentation of this disease, but in the last several
years, fewer and fewer cases have been seen and diagnosed. This is due primarily to the
development of a safe and effective vaccine, which has been studied extensively. In the
future, primary care clinicians will see less of this disease, although the potential severity of
disease and associated risk of morbidity and mortality necessitate a continued awareness of
the clinical features and risk of complications. The American Academy of Pediatrics (AAP)
and the Advisory Committee on Immunization Practices (ACIP) of the Centers for
Disease Control and Prevention (CDC) have set a goal for more than 90% of American
children to be immunized against varicella by the year 2010.

Definitions
Chickenpox is the clinical syndrome that results from primary infection with varicella-
zoster virus (VZV), which is a herpesvirus. Herpes zoster (also called “shingles” or
“zoster”) appears after reactivation of latent VZV, which can occur at any time after a
primary infection. Disseminated zoster can occur after reactivation in immunocompro-
mised patients and consists of severe rash with systemic findings. Congenital varicella
syndrome, or varicella embryopathy, is the result of varicella infection in a woman during
the first or second trimester of pregnancy.

Epidemiology
Varicella infection is more common during the late winter and early spring. The disease
also is more prevalent in temperate areas than in tropical climates. Prior to the development
of the vaccine, an estimated 4 million cases, with 10,000 hospitalizations and 100 deaths,
occurred in the United States each year, most frequently involving children younger than
the age of 10 years. Since then, reports of varicella infection have declined. The CDC has
encouraged states to improve surveillance for varicella, but only 14 states maintained a
continuous level of reporting from 1987 to 1997.
Varicella infection is found only in humans. The mode of transmission is person-to-
person via direct contact with infected mucosa or airborne particles from respiratory
secretions. Transplacental passage of the virus also can occur. Transmission to susceptible
household contacts is expected (approximately 90%), and secondary cases often are more
severe than index cases. Nosocomial transmission has been reported. Subclinical varicella
can occur, as indicated by many adults who have no history of the disease demonstrating
detectable antibodies to the virus. Immunity after natural varicella infection is considered
lifelong.

*Assistant Professor of Clinical Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA.

372 Pediatrics in Review Vol.24 No.11 November 2003

Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018

Figure 1. Typical varicella vesicles.
The incubation period for chickenpox is 10 to
21 days, with most people being infected within 14 to
16 days of exposure. Communicability is highest in the
period from 1 to 2 days prior to the appearance of the
rash to 1 to 2 days after its onset. Healthy children may
be considered noncontagious after all lesions have
crusted over, although communicability may be pro-
longed in immunocompromised patients who have se-
vere infection. Susceptible children may become infected
with varicella after direct contact with active zoster le-
sions because these lesions contain infectious virus, but
not after exposure to respiratory secretions from individ-
uals who have zoster. Exposure to children who have
chickenpox is not believed to reactivate zoster.
Pathogenesis
After a person is exposed to VZV, the virus undergoes
two phases of replication during the incubation period.
Primary replication, which begins 3 to 4 days after expo-
sure, occurs in the oropharynx and regional lymph nodes
and is followed by a period of primary viremia. A second-
ary viremia, with intracellular replication within the re-
ticuloendothelial system, occurs 10 to 21 days after
exposure. Late in the secondary viremic phase, the virus is
delivered to the skin, at which time the typical cutaneous
lesions become evident. These lesions may continue to
develop for the next 3 to 7 days as a result of infected
mononuclear cells. The virus also is carried to the respi-
ratory mucosa toward the end of the incubation period,
Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018
infectious diseases varicella
which is the reason for communica-
bility before the onset of rash. Fol-
lowing viremia, the virus becomes
latent in dorsal root ganglia cells. It
remains there until reactivation, at
which time the virus travels back to
the skin along the sensory nerve.
Reactivation likely is due to declin-
ing cell-mediated immunity, which
explains the increased incidence in
the elderly and in immunocompro-
mised patients.
The viremic phase of varicella
infection may be prolonged in indi-
viduals who are immunocom-
promised. Because cell-mediated
immunity plays a role in the termi-
nation of viremia, patients who
have this type of immunodeficiency
are more at risk than those who
have primary humoral immunode-
ficiency. Prolonged viremia is the
reason for prolonged communicability and dissemina-
tion of the virus to organs such as the heart, brain, lungs,
and liver. Accordingly, immunocompromised children
are at greater risk for developing complications such as
pneumonia, meningoencephalitis, and hepatitis.
Clinical Aspects
Clinical Presentation
The rash of varicella often is preceded by a 24- to
48-hour period of fever, malaise, and other systemic
symptoms. The typical exanthem begins as erythema-
tous, pruritic macules that develop into papules and
fluid-filled vesicles. The crusting of the vesicles is the final
stage of the lesions before resolution, and scarring occurs
rarely. One of the most characteristic features of the
exanthem is the presence of all stages of lesions simulta-
neously (Fig. 1). The average number of lesions is ap-
proximately 300 to 400, but the number can vary from
fewer than 50 in healthy children to more than 1,000 in
immunocompromised children or in severe infection.
The average length of time from the development of the
initial lesion to the crusting of all lesions is approximately
4 to 5 days.
Neonates born to women who develop primary vari-
cella infection 5 days before to 2 days after delivery are at
increased risk of severe varicella infection, which may be
fatal. Clinical features of perinatally acquired varicella
include severe rash, pneumonia, hepatitis, and death in
20% to 30% of cases. Infants born to mothers who are
Pediatrics in Review Vol.24 No.11 November 2003 373
infectious diseases varicella

infected before 5 days prior to de-

livery have less severe disease be-
cause of the transplacental transfer
of VZV-specific maternal immuno-
globulin G.
Congenital varicella syndrome
results when a mother is infected
within the first 20 weeks of gesta-
tion. “Zigzag” skin scarring and
limb atrophy are characteristic find-
ings of this embryopathy. Brain ab-
normalities, including hydrocepha-
lus and microcephaly, and eye
abnormalities, such as cataracts and
chorioretinitis, also may occur.

Complications
The most common complication of
varicella is secondary bacterial in-
fection, usually with Streptococcus Figure 2. Secondary infection in patient who has varicella. Photo courtesy of Joseph
pyogenes or S aureus (Fig 2). S pyo- Zenel, MD.
genes, or group A Streptococcus
(GAS), is emerging as an increas-
ingly common pathogen in patients who have varicella,
and it may cause severe invasive disease. A multicenter
study published in 2001 found that the risk of invasive
GAS infection was somewhat increased in nonwhite chil-
dren in low-income households, in persons exposed at
home, and in persons who had a long duration of fever.
Several case reports and studies have suggested a causal
relationship between the use of nonsteroidal anti-
inflammatory drugs (NSAIDs) and the development of
necrotizing GAS infections, but the previously noted
multicenter study found no clear causal association. Par-
ents were more likely to administer anti-inflammatory
and antipyretic medications to children who had more
severe varicella disease, and it is known that severe vari- Most lesions resolve within 2 weeks. Immunocompro-
cella disease can predispose a patient to invasive GAS
disease. Thus, the association between NSAID use and
GAS infection may be due to these confounding vari-
ables.
Other invasive complications of varicella infection
include pneumonitis, meningoencephalitis, hepatitis,
arthritis, and glomerulonephritis. These complications
are more common in children who are immunocompro-
mised, especially those who have T-cell defects, leuke-
mia, or lymphoma. Hemorrhagic varicella is a severe
form of the disease that also is found more commonly in
immunocompromised patients. Hemorrhagic varicella
carries a 70% mortality risk. Varicella also is one of the
most common causes of postviral cerebellar ataxia and
postviral transverse myelitis.
Herpes Zoster
Zoster, or “shingles,” is characterized by vesicles clus-
tered in a dermatomal distribution. The initial presenting
symptom frequently is pain at the future site of the
lesions, which usually arise within a few days. Pruritus
also may occur. The most common sites for the develop-
ment of zoster lesions are those supplied by the trigem-
inal nerve and the thoracic ganglia. New lesions occur
over 2 to 3 days, then begin to crust over the next week.
mised persons may experience a prolonged course or
develop disseminated zoster, which is characterized by a
severe, varicelliform rash with systemic findings such as
pneumonitis, hepatitis, and disseminated intravascular
coagulation. The development of herpes zoster in chil-
dren does not necessarily imply an occult malignancy or
other immunodeficiency.
The most common complication of herpes zoster is
postherpetic neuralgia, which is defined as pain that lasts
longer than 1 month. This is uncommon in children and
occurs most often in persons older than 50 years of age.
Immunocompromised patients also have an increased
risk of this complication.

374 Pediatrics in Review Vol.24 No.11 November 2003

Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018
 infectious diseases varicella

Acyclovir Dosing for Varicella and Zoster

Table 1. acyclovir is not routinely recom-
mended for healthy children
Infections younger than 12 years of age be-
cause the disease generally has a
Infection Dosing
benign, self-limited course. How-
Varicella—immunocompetent 80 mg/kg per day PO divided qid for 5 d ever, studies have shown a moder-
patient Maximum dose, 3,200 mg/d ate decrease in the severity of symp-
Varicella—immunocompromised 30 mg/kg per day IV divided tid for 7 to 10 d
patient (<1 y of age) toms if acyclovir is used within
2
1,500 mg/M per day IV divided tid for 7 to 24 hours of the onset of the rash.
10 d (>1 y of age) Oral acyclovir may be consid-
Zoster—immunocompetent and 30 mg/kg per day IV divided tid for 7 to 10 d ered for those at risk for more se-
immunocompromised (<1 y of age)/1,500 mg/M2 per day vere infection, including children
patients divided tid for 10 d (>1 y of age)
OR older than age 12 years, persons
4 g/d PO in 5 divided doses for 5 to 7 d who have chronic disease, and per-
(>12 y of age) sons who are taking chronic aspirin
or corticosteroid therapy. If oral
acyclovir is used, it should be initi-
Diagnosis ated early in the course of the exanthem (see Table 1 for
The clinical appearances of primary varicella and herpes recommended doses).
zoster infections are so characteristic that laboratory test- Intravenous acyclovir should be used for immuno-
ing often is not necessary. However, several diagnostic compromised patients who have varicella-zoster infec-
tests are available if the diagnosis is in question. A Tzanck tion and should be initiated within 24 hours of the onset
smear performed on a vesicle scraping shows multinucle- of the rash (Table 1). In general, acyclovir is a safe
ated giant cells, but it does not distinguish between medication, although adverse effects such as nausea,
varicella zoster and herpes simplex. Viral culture and diarrhea, and renal toxicity have been reported. Patients
direct fluorescent antigen (DFA) performed on a vesicle who have renal dysfunction should receive reduced
scraping can differentiate between the two; the DFA is doses. Intravenous foscarnet is available for the treatment
more rapid and sensitive than the culture. The virus is of acyclovir-resistant infections. Because renal toxicity
isolated best from vesicle scrapings during the first 3 to and electrolyte abnormalities are the most important
4 days of the rash. A polymerase chain reaction per- complications of foscarnet therapy, serum creatinine and
formed on vesicle fluid often can identify and help to electrolyte levels should be monitored closely.
differentiate wild type varicella from vaccine-induced Currently, acyclovir is the treatment of choice for
varicella. herpes zoster infections in both immunocompromised
Immunity to varicella zoster may be determined in and immunocompetent children (see Table 1 for dos-
immunocompetent persons by a significant increase in ing). Famcicyclovir and valacyclovir are effective treat-
serum antibody (immunoglobulin G) to varicella. Latex ments for zoster infections in adults, although these
agglutination is more sensitive than enzyme immunoas- medications have not been studied adequately for use in
say in determining immunity, including vaccine-induced the pediatric population.
immunity. These tests are less reliable in immunocom-
promised individuals. Postexposure Prophylaxis
Varicella vaccine and varicella-zoster immune globulin
Management (VZIG) are both available for the prevention of disease in
Treatment susceptible persons exposed to VZV. Significant expo-
The treatment of primary varicella-zoster infection is sure includes household contacts, close play or hospital
supportive, including antipyretics and antihistamines or contacts, newborns born to mothers who develop vari-
oatmeal baths to control fever and itching. Because of the cella 5 days prior to or 2 days after delivery, and those
risk of Reye syndrome, aspirin should be avoided. As who have direct contact with active zoster lesions. Sus-
mentioned previously, case reports have supported the ceptibility should be determined by the history of previ-
avoidance of NSAIDs as well, although the association ous disease, keeping in mind that 70% to 90% of adults
between the use of these agents and the development of who do not have a reliable history of varicella are im-
invasive GAS infection has not been proven. The use of mune. For immunocompetent persons, serologic testing

Pediatrics in Review Vol.24 No.11 November 2003 375

Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018
infectious diseases varicella
is reliable but not necessary. Immunocompromised per-
sons demonstrate unreliable results.
Varicella vaccine has been shown to prevent or modify
the disease course if administered to healthy susceptible
children within 3 days (and possibly 5 days) of exposure.
If the susceptible child is in the prodromal phase of
varicella disease, vaccine administration does not increase
the risk of developing more severe disease or vaccine-
associated adverse effects. The vaccine also is safe for
persons who have immunity from a previous subclinical
infection.
VZIG is effective in preventing disease if administered
within 4 days of exposure to varicella; maximum effec-
tiveness is achieved if it is administered as soon as possible
after exposure is recognized. VZIG is administered intra-
muscularly, and the most common adverse effect is pain
at the injection site. Patients who receive monthly intra-
venous immune globulin (IVIG) do not require VZIG if
the last IVIG infusion was administered up to 3 weeks
before exposure. In the case of significant exposure,
VZIG should be given to suscep-
tible immunocompromised chil-
dren and adolescents, susceptible
healthy adults, susceptible preg-
nant women, and newborns
whose mothers developed vari-
cella 5 days before to 2 days after
Intravenous
be used for immunocompromised patients
delivery. Hospitalized preterm in- who have varicella-zoster infection and
fants who are younger than
should be initiated within 24 hours of the
28 weeks’ gestation should re-
ceive VZIG after exposure, re- onset of the rash.
gardless of maternal immune sta-
tus; those older than 28 weeks’
gestation should receive it if the mother lacks a reliable
history or serologic evidence of immunity. Bone marrow
transplant recipients should be given VZIG after expo-
sure, regardless of prior history of varicella. The duration
of protection from varicella after VZIG administration is
unknown.
Isolation
Airborne and contact precautions should be initiated for
hospitalized patients who have varicella for at least 5 days
after the onset of the rash and maintained until all vesicles
are crusted. Exposed susceptible patients should be kept
on airborne and contact precautions from 8 to 21 days
after onset of the rash in the index case. These precau-
tions also should be practiced for neonates born to
mothers who had varicella until the infants are 21 days of
age. Patients who receive VZIG should be isolated for a
total of 28 days.
376 Pediatrics in Review Vol.24 No.11 November 2003
Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018
Immunocompromised patients who have zoster and
immunocompetent patients who have disseminated zos-
ter should be placed on airborne and contact precautions
for the entire duration of the illness. Contact precautions
are recommended for immunocompetent persons who
have localized zoster until all lesions are crusted over.
Immunocompetent children who have uncompli-
cated varicella infection may return to school when all
lesions are crusted over. Immunocompromised children
and other children who have prolonged or complicated
courses should not return to school until the rash has
resolved. Children and adult child care workers who have
zoster may return to school or work if all lesions can be
covered.
Susceptible exposed hospital and child care staff
should be excused from patient or child contact from 8 to
21 days after exposure to an infected person. If exposure
to an infected person does not result in disease in suscep-
tible personnel, immunization with the vaccine is recom-
mended.
acyclovir should
Prevention
The varicella vaccine, which was licensed for use in March
1995, is a live-attenuated preparation of the wild Oka
strain of varicella. The AAP and ACIP recommended its
routine use in susceptible children older than 12 months
of age shortly after its licensure. After evaluation of the
safety and efficacy of the vaccine, these groups continue
to support this recommendation.
Despite these recommendations, many children re-
main unimmunized against varicella. The AAP Commit-
tee on Infectious Diseases has identified possible barriers
to universal immunization, including the misconception
that varicella is always a mild disease, concern over vac-
cine safety, and concern about waning immunity. Many
pediatricians are not recommending the varicella vaccine
routinely, and only a few states require proof of disease or
vaccination before the child enters school or child care.
One study conducted in an urban environment showed

that parents are significantly influenced by their pediatri-
cian’s views on vaccination against varicella. This sug-
gests that improved efforts to educate community pedi-
atricians on the safety and efficacy of the vaccine are
necessary to achieve universal vaccination.
A safety surveillance of the varicella vaccine evaluated
adverse events reported to the United States Vaccine
Adverse Event Reporting System (VAERS) from March
1995 to July 1998. More than 6,500 cases of adverse
events were reported during this time, which is a rate of
67.5 per 100,000 doses sold. Of these, the most com-
mon were rash, possible vaccine failure, and injection site
reactions. Rashes, most often vesicular, accounted for
more than 50% of the reports. Of the specimens tested,
wild-type varicella was found in 61% (with symptoms
occurring approximately 1 week after immunization),
and the Oka strain was identified in 31% (with symptoms
occurring an average of 4 weeks after immunization).
Possible vaccine failure was reported in approximately
20%, and many of these were reported following subse-
quent negative serologic tests. Injection site reactions
occurred in 8.7% of patients and usually occurred within
1 week of vaccination.
More serious but rare adverse events have been re-
ported, including pneumonia, hepatitis, erythema multi-
forme and Stevens-Johnson syndrome, thrombocytope-
nia, anaphylaxis, and neurologic events, such as seizures
and neuropathies. In most of these events, no evidence
linked administration of the vaccine to the development
of symptoms. In addition, evidence of wild-type virus was
found in many patients who had both mild and serious
adverse events, highlighting the importance of the contin-
ued presence of wild-type virus in the community.
Herpes zoster has been reported after vaccine admin-
istration, but it is much less frequent than zoster occur-
ring after natural varicella and often is associated with the
isolation of wild-type virus, suggesting infection prior to
vaccination. Transmission of vaccine-associated virus is
extremely rare and occurs only if a rash develops in the
vaccinee. The risk of developing disease after this type of
exposure is so rare that the routine use of VZIG or
acyclovir as prophylaxis is not recommended, even in
immunocompromised patients.
In addition to being safe, the varicella vaccine has
been found to be efficacious. Numerous studies have
been performed since its licensure, and the evidence
suggests that the vaccine is approximately 85% to 90%
effective in preventing all forms of the disease and 95% to
100% effective in preventing moderate-to-severe disease.
Recently, a study of more than 1,100 healthy children
evaluated the persistence of antibody 6 years after vacci-
Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018
infectious diseases varicella
Table 2. Dosing for Varicella Vaccine
Age Dosing
12 to 18 mo 0.5 mL SC/IM—single dose
19 mo to 13 y 0.5 mL SC/IM—single dose (at any
time)
13 y to adulthood 0.5 mL SC/IM—2 doses, 4 to
8 weeks apart
nation. This study determined that the antibody persis-
tence rate over the 6 years was 99%, with breakthrough
events occurring in 0.2% to 2.3% of children per year.
Breakthrough cases were generally mild. Children who
have high levels of varicella antibody after vaccination
appear to be at decreased risk for developing break-
through infection. Studies performed to date have sup-
ported the evidence that most vaccinees have long-term
persistence of antibodies to VZV. Further studies are
necessary to determine the role, if any, of booster doses
of the varicella vaccine in providing lifelong immunity.
The varicella vaccine should be administered to all
healthy susceptible children older than 1 year of age. The
AAP and ACIP also recommend its use up to 3 days after
exposure to varicella (see Table 2 for dosing and admin-
istration). Contraindications to vaccination include con-
current moderate-to-severe febrile illness, chronic high-
dose steroid use (2 mg/kg per day for ⱖ14 d), preg-
nancy, and a history of anaphylaxis with any component
of the vaccine, including gelatin and neomycin. In addi-
tion, the vaccine should not be administered routinely to
children who have cell-mediated immunodeficiencies, leu-
kemia, lymphoma, or other bone marrow malignancies.
One exception to the contraindications is the child
who has acute lymphoblastic leukemia, has been in re-
mission for at least 1 year, and has reasonable lymphocyte
and platelet counts. In these patients, immunization has
been shown to be safe and effective, although approval
by institutional review boards currently is required for its
use. Another exception is the child who has human
immunodeficiency virus (HIV) infection and is asymp-
tomatic or mildly symptomatic. A recently published
study demonstrated that such HIV-infected children
who received two doses of vaccine had seroconversion
rates of 60%, with adverse effects similar to those seen in
immunocompetent children.
Household contacts of immunocompromised indi-
viduals may receive the vaccine, but they should avoid
direct contact with the immunocompromised person if a
rash develops after vaccination. Immunodeficiency
should be excluded before vaccination in a person whose
Pediatrics in Review Vol.24 No.11 November 2003 377
infectious diseases varicella
family history includes hereditary immunodeficiency.
Administration of the vaccine should be postponed until
3 to 11 months after the administration of IVIG, de-
pending on the dose of IVIG used. IVIG should be
withheld until 2 weeks after the varicella vaccine is given.
Summary
Varicella infection is generally a benign, self-limited dis-
ease, but serious complications can occur, especially in
immunocompromised children, neonates, and adults.
Ongoing education on the risks of infection and the
benefits of vaccination is necessary to minimize the inci-
dence as well as the morbidity and mortality of this
disease.
Suggested Reading
American Academy of Pediatrics. Varicella-zoster virus. In: Picker-
ing LK, ed. 2000 Red Book: Report of the Committee on Infectious
378 Pediatrics in Review Vol.24 No.11 November 2003
Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018
Diseases. 25th ed. Elk Grove Village, Ill: American Academy of
Pediatrics; 2000:624 – 628
Committee on Infectious Diseases. Varicella vaccine update. Pedi-
atrics. 2000;105:136 –141
Lesko SM, O’Brien KL, Schwartz B, Vezina R, Mitchell A. Invasive
group A streptococcal infection and nonsteroidal antiinflamma-
tory drug use among children with primary varicella. Pediatrics.
2001;107:1108 –1115
Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-
infected children with varicella vaccine. J Pediatr. 2001;139:
305–310
Skull SA, Wang EEL. Varicella vaccination – a critical review of the
evidence. Arch Dis Child. 2001;85:83–90
Taylor JA, Newman RD. Parental attitudes toward varicella vacci-
nation. Arch Pediatr Adolesc Med. 2000;154:302–306
Vessey SJR, Chan CY, Kuter BJ, et al. Childhood vaccination
against varicella: persistence of antibody, duration of protection,
and vaccine efficacy. J Pediatr. 2001;139:297–304
Wise RP, Salive ME, Braun MM, et al. Postlicensure safety
surveillance for varicella vaccine. JAMA. 2000;284:1271–
1279
 infectious diseases varicella

PIR Quiz
Quiz also available online at www.pedsinreview.org.

6. A previously well 13-year-old boy develops fever and a papulovesicular and pustular rash over his trunk.
Assuming that this represents acute varicella-zoster infection, you would expect:
A. Acetylsalicylic acid to be a reasonable choice for fever management.
B. Appreciable benefit from varicella-zoster immune globulin.
C. Low risk of severe disease.
D. Occasional animal-to-human transmission.
E. Persistent infection of primary sensory neurons.

7. A healthy 12-year-old girl who had chickenpox 6 years ago develops a linear, pruritic, and vesicular
eruption on her left chest. You diagnose herpes zoster. In this situation, the most appropriate next step is
to:
A. Initiate a thorough evaluation for occult malignancy.
B. Institute airborne and contact isolation until all lesions are crusted over.
C. Prescribe a course of oral acyclovir.
D. Recommend a prophylactic topical antibiotic.
E. Recommend home schooling until all lesions are crusted over.

8. A previously well 6-year-old girl develops chickenpox. The complication for which she is most at risk is:
A. Glomerulonephritis.
B. Hemorrhagic varicella.
C. Invasive group A streptococcal disease.
D. Pneumococcal meningitis.
E. Varicella pneumonia.

9. A woman develops chickenpox 3 days before delivery. The labor and delivery prove uneventful. The baby
girl is term, appropriate for gestational age, and appears healthy. In this situation, benefit/risk analysis
mandates the administration of:
A. Intramuscular varicella-zoster immune globulin.
B. Intravenous foscarnet.
C. Only observation.
D. Oral acyclovir.
E. Subcutaneous varicella vaccine.

10. You are asked to discuss the varicella vaccine with a group of residents. Of the following, the most
appropriate statement to include in your discussion is that:
A. Postexposure varicella vaccine does not prevent or modify disease.
B. Pre-exposure varicella vaccine reliably prevents severe disease.
C. Transmission of varicella vaccine virus is a common event.
D. Vaccine-induced antibody falls to nonprotective levels in most children within 6 years.
E. Varicella vaccine causes severe reactions in individuals who have developed immunity after exposure to
the wild virus.

Pediatrics in Review Vol.24 No.11 November 2003 379

Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018
 Varicella
Robin English
Pediatrics in Review 2003;24;372
DOI: 10.1542/pir.24-11-372

Updated Information & including high resolution figures, can be found at:
Services http://pedsinreview.aappublications.org/content/24/11/372
References This article cites 7 articles, 3 of which you can access for free at:
http://pedsinreview.aappublications.org/content/24/11/372#BIBL
Subspecialty Collections This article, along with others on similar topics, appears in the
following collection(s):
Infectious Disease
http://classic.pedsinreview.aappublications.org/cgi/collection/infectio
us_diseases_sub
Vaccine/Immunization
http://classic.pedsinreview.aappublications.org/cgi/collection/vaccine
:immunization_sub
Permissions & Licensing Information about reproducing this article in parts (figures, tables) or
in its entirety can be found online at:
http://classic.pedsinreview.aappublications.org/site/misc/Permissions
.xhtml
Reprints Information about ordering reprints can be found online:
http://classic.pedsinreview.aappublications.org/site/misc/reprints.xht
ml

Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018

 Varicella
Robin English
Pediatrics in Review 2003;24;372
DOI: 10.1542/pir.24-11-372

The online version of this article, along with updated information and services, is
located on the World Wide Web at:
http://pedsinreview.aappublications.org/content/24/11/372

Pediatrics in Review is the official journal of the American Academy of Pediatrics. A monthly
publication, it has been published continuously since 1979. Pediatrics in Review is owned,
published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point
Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2003 by the American Academy of
Pediatrics. All rights reserved. Print ISSN: 0191-9601.

Downloaded from http://pedsinreview.aappublications.org/ by guest on July 2, 2018